辉瑞/生物科技公司 COVID-19 疫苗接种后第 1 或第 2 剂后 3 周，70-80 岁人群的抗体反应较强，英国，2021 年 1 月至 2 月。
Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021.
机构信息
Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom.
Virus Reference Department, National Infection Service, Public Health England, London, United Kingdom.
出版信息
Euro Surveill. 2021 Mar;26(12). doi: 10.2807/1560-7917.ES.2021.26.12.2100329.
Sera were collected from 185 adults aged ≥ 70 years in London to evaluate the immune response to COVID-19 vaccines. A single dose of Pfizer/BioNtech vaccine resulted in > 94% seropositivity after 3 weeks in naïve individuals using the Roche Spike antibody assay, while two doses produced very high spike antibody levels, significantly higher than convalescent sera from mild-to-moderate PCR-confirmed adult cases. Our findings support the United Kingdom's approach of prioritising the first dose and delaying the second dose of COVID-19 vaccine.
从伦敦 185 名年龄≥70 岁的成年人中采集血清，以评估对 COVID-19 疫苗的免疫反应。罗氏棘突抗体检测法显示，在未接种过疫苗的个体中，接种辉瑞/生物技术公司的一剂疫苗 3 周后，血清抗体阳性率超过 94%，而接种两剂疫苗则产生了非常高的棘突抗体水平，明显高于轻度至中度经 PCR 确诊的成年患者的恢复期血清。我们的研究结果支持英国优先接种第一剂 COVID-19 疫苗并推迟第二剂的做法。
Zotero 插件